A phase IIb study has shown that pegylated IFN-λ1 treatment can produce a similar or improved immune response against chronic hepatitis C virus infection with fewer side effects when compared to IFN-I (128). The gene discussed is IFNL1; the disease is chronic hepatitis C virus infection.